Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.
The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.
Browse Complete Report with TOC @ http://www.marketresearchstore.com/report/global-cardiovascular-disease-market-to-2022-sanofi-85409
There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market with the advent of statins such as Lipitor, the best-selling drug of all time, which produce marked reductions in cholesterol levels. More recently, the commonly used direct factor Xa inhibitors which produce anti-coagulant effects, have been made available for oral administration and the advent of PCSK9 inhibitors provide a viable alternative dyslipidemia treatment for when statins are unsuitable or inefficient. There are currently 1368 pipeline drugs within the cardiovascular disease market, the largest therapy area being thrombosis, with 406 pipeline products indicated for treatment or prevention of thrombotic events.
Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as the aforementioned PCSK9 inhibitors and direct factor Xa inhibitors.
To Get Sample Copy of Report visit @ http://www.marketresearchstore.com/report/global-cardiovascular-disease-market-to-2022-sanofi-85409#RequestSample
Scope
Analysis of innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events.
A brief introduction to CVD, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
Identification of key marketed products, with a focus on historical and forecast sales patterns and an overview of each drug’s mechanism of action.
